NV106

About Nanovalent Pharmaceuticals

Nanovalent Pharmaceuticals is a preclinical-stage biotech leveraging its unique Hybrid Polymerized Liposomal Nanoparticle (HPLN) platform to create next-generation targeted nanotherapeutics, termed nADC/TNS. The company's lead candidate, NV103/NV105, is approaching IND status and targets CD99-expressing tumors such as glioblastoma, Ewing sarcoma, pancreatic, and ovarian cancers. Its platform aims to overcome limitations of traditional ADCs by enabling higher drug payloads, enhanced tumor targeting, and reduced systemic toxicity, with potential applications beyond oncology in neurological diseases due to blood-brain barrier penetration.

Therapeutic Areas

Other Glioblastoma and other B7H3 (CD276) expressing tumors Drugs